Skip to main content
SpringerLink
Log in

Tumor necrosis factor-α blocking agent as a treatment for nephrotic syndrome

  • Brief Report
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

We report a 13-year-old boy with refractory nephrotic syndrome (minimal change with mesangial proliferation) who failed the standard treatment protocols. There was some temporary response to large steroid doses, but even the Mendoza protocol could not induce remission. We show suppression of the proteinuria with Infliximab (Remicade) with tapering of steroids. Serial serum levels of tumor necrosis factor (TNF)-α are shown and discussed. We suggest studying the TNF-α blocking agents as optional treatment for nephrotic syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Suranyl MG, Guasch A, Hall BM, Myers BD (1993) Elevated levels of TNFα in the nephrotic syndrome in humans. Am J Kidney Dis 22:622

    Google Scholar 

  2. Bakr A, Shokeir M, El-Chenawi F, El-Husseni F, Abdel-rachman A, El-Ashry R (2003) TNFα production from mononuclear cells in nephrotic syndrome. Pediatr Nephrol 18:516–520

    PubMed  Google Scholar 

  3. McCarthy ET, Sharma R, Scharma M, Li JZ, Ge XL, Dileezpan KN (1998) TNFα increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol 9:433–438

    CAS  PubMed  Google Scholar 

  4. Pai R, Ha H, Kirschenbaum MA, Kamanna VS (1996) Role of tumor necrosis factor alpha on mesangeal cell MCP-1 expression and monocyte migration: mechanisms mediated by signal transduction. J Am Soc Nephrol 7:914–923

    CAS  PubMed  Google Scholar 

  5. Drewe E, McDermott EM, Powell RJ (2000) Treatment of the nephrotic syndrome with Etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med 343:1044–1045

    Article  CAS  PubMed  Google Scholar 

  6. Verschueren P, Lensen F, Lerut E, Claes K, De Vos R, Van Damme B, Westhovens R (2003) Benefit of anti-TNFα treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann Rheum Dis 62:368–369

    Article  CAS  PubMed  Google Scholar 

  7. Pusey C (2001) Efficacy of anti-TNFα in the treatment of nephrotoxic nephritis. Symposium on glomerulonephritis and anti-GBM disease: World Congress of Nephrology (ASN), USA (http://www.hdcn.com/symp/01asn/pu/pusey.htm)

  8. Bircan Z, Kara B (2003) Intravenous cyclophosphamide is the drug of choice for steroid dependent nephrotic syndrome. Pediatr Int 45:65–67

    Article  CAS  PubMed  Google Scholar 

  9. Ducloux D, Bresson-Vautrin C, Chalopin J (2001) Use of pentoxifylline in membranous nephropathy. Lancet 357:1672–1673

    Article  CAS  PubMed  Google Scholar 

  10. Cornillie F, Shealy D, D’Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P (2001) Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther 15:463–473

    Article  CAS  PubMed  Google Scholar 

  11. Barak V, Nisman B, Polliack A (1999) The tumor necrosis factor family and correlation with disease activity and response to treatment in hairy cell leukemia. Eur J Haematol 62:71–75

    CAS  PubMed  Google Scholar 

  12. Li Naisan Yu Dondhui (1992) Study on toxicokinetics of crude extract from Tripterygium wilfordii. J Chin Phram Univ 23:25–26

    Google Scholar 

  13. Zhang Xiao Chen Shunle (1993) Effect of Tripterygium wilfordii Hook F on contrasuppressor T cells in SLE nephritic patients. Chin J Immunol 9:230–231

    Google Scholar 

  14. Qiu D, Kao PN (2003) Immunosuppressive and anti-inflammatory mechanisms of Triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. F. Drugs 4:1–18

    Article  CAS  Google Scholar 

Download references

Acknowledgement

It is important to note that the first author of this report is the patient’s father. The impact that this relationship may have had on treatment decisions for the patient has been carefully considered by all of the authors. The treatment protocol received support from other medical experts, as well as the approval of the local Helsinki committee.

Author information

Authors and Affiliations

  1. Division of Internal Medicine, Shaare Zedek Medical Center, Jerusalem, Israel

    David Raveh, Ovadia Shemesh, Yaakov Jack Ashkenazi & Robert Winkler

  2. Immunology Laboratory, Oncology Department, Hadassah Medical Center, Jerusalem, Israel

    Vivian Barak

  3. Infectious Disease Unit, Shaare Zedek Medical Center, Jerusalem, Israel

    David Raveh

Authors
  1. David Raveh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ovadia Shemesh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yaakov Jack Ashkenazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert Winkler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vivian Barak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Raveh.

Additional information

Editorial comment Before the decision was made to accept this report for publication, it was carefully considered by both medical and ethical experts with special regard for the acknowledged relationship between the patient and one of the treating physicians. We believe that this “hypothesis paper” may be of interest to our readership.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raveh, D., Shemesh, O., Ashkenazi, Y.J. et al. Tumor necrosis factor-α blocking agent as a treatment for nephrotic syndrome. Pediatr Nephrol 19, 1281–1284 (2004). https://doi.org/10.1007/s00467-004-1573-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-004-1573-2

Keywords

Search

Navigation